[go: up one dir, main page]

WO2020263577A1 - Nouvelle formulation pour le traitement de l'inflammation et de la douleur - Google Patents

Nouvelle formulation pour le traitement de l'inflammation et de la douleur Download PDF

Info

Publication number
WO2020263577A1
WO2020263577A1 PCT/US2020/037133 US2020037133W WO2020263577A1 WO 2020263577 A1 WO2020263577 A1 WO 2020263577A1 US 2020037133 W US2020037133 W US 2020037133W WO 2020263577 A1 WO2020263577 A1 WO 2020263577A1
Authority
WO
WIPO (PCT)
Prior art keywords
beta
cannabidiol
complexed
caryophyllene
cyclodextrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2020/037133
Other languages
English (en)
Inventor
Michael Farber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mountain Valley MD Inc
Original Assignee
Mountain Valley MD Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mountain Valley MD Inc filed Critical Mountain Valley MD Inc
Publication of WO2020263577A1 publication Critical patent/WO2020263577A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • the present invention relates to inflammation and pain treatment. More specifically, synergistic compositions for alleviating or preventing inflammatory mediated disorders in mammals and various forms of degenerative musculoskeletal diseases resulting therefrom, such as rheumatoid arthritis and osteoarthritis.
  • the present invention further relates to compositions exhibiting the synergistic activity of mediating inflammation through the simultaneous effect of the COX2, CB2 and TPRV1 pathways.
  • the compositions comprise complexed curcuminoids and complexed cannabidiol optionally containing other ingredients, which shows a synergistic anti inflammatory and antioxidant property.
  • COX-2 Constitutive cyclooxygenase
  • PGs prostaglandins
  • COX-2 constitutive COX
  • COX-2 functions in both inflammation and control of cell growth. While COX-2 is inducible in many tissues, it is present constitutively in the brain and spinal cord, where it may function in nerve transmission for pain and fever.
  • the two isoforms of COX are nearly identical in structure but have important differences in substrate and inhibitor selectivity and in their intracellular locations.
  • Protective PGs which preserve the integrity of the stomach lining and maintain normal renal function in a compromised kidney, are synthesized by COX-1.
  • COX-2 in immune cells are central to the inflammatory process.
  • the discovery of COX-2 has made possible the design of new drugs and synergistic compositions that reduce inflammation without removing the protective PGs in the stomach and kidney made by COX-1.
  • Curcuminoids belonging to the cinnamoyl methane group. Curcuminoids are present to the extent of 3 to 5 percent in the raw material. They are considered the most important active ingredients and are believed to be responsible for the biological activity of Curcuma longa. Though their major activity is anti-inflammatory, curcuminoids have been reported to possess antioxidant, antiallergic, wound healing, antispasmodic, antibacterial, antifungal, antitumor and antiHIV activity as well. Curcumin was isolated in 1815 and structurally defined in 1910. Other major curcuminoids isolated from Curcuma longa include demethoxycurcumin and bisdemethoxycurcumin.
  • Curcuminoids may be found in other botanicals in addition to Curcuma longa. Such as Curcuma xanthorrhiza and Curcuma Zedoaria. Curcuminoids are well known for their anti inflammatory activity. Turmeric is one of the oldest anti-inflammatory drugs used in Ayurvedic medicine. The pharmacokinetics involving the safety, toxicity, dose range and biological properties of turmeric and its components, including curcumin is known, and the turmeric is readily available in various food stores. Curcumin is not highly bioavailable orally. The anti-inflammatory properties of curcumin were shown to inhibit the 5-lipoxygenase activity
  • Cannabidiol elevates anandamide and inhibits MCP-2 IL6 and IL8 through both CB2 and TPRV 1 signaling (Petrosino S et al J Pharmacol Exp Ther 2018)
  • Cannabidiol is a nonpsychoactive cannabinoid isolated from the hemp plant.
  • Cannabidiol has low water solubility and very low oral
  • cannabidiol is a weak CB2 agonist its CB2 agonist activity may be synergistically enhanced through combination with one of the naturally occurring terpenes also found in hemp notably beta-caryophyllene.
  • Beta-caryophyllene is a highly volatile terpene compound found in hemp and therefore it must also be complexed to provide processing stability and higher bioavailability.
  • the combination of complexed cannabidiol and beta-caryophyllene provide enhanced activation of the CB2 pathway as well as TPRV 1 activation.
  • a composition of complexed curcuminoids and complexed cannabidiol with beta- caryophyllene, and optionally other ingredients for reducing or preventing inflammation of joint tissues, for treating arthritis or other inflammatory conditions and reducing pain therein has not yet been discovered.
  • a composition comprising complexed curcuminoids, complexed cannabidiol with beta-caryophyllene and optionally other ingredients to synergistically inhibit COX-2, and activate
  • U.S. Pat. No. 6,521,271 described the methods of promoting the improvement of skin condition by administering a turmeric component and glycolic acid to a patient afflicted with a skin disorder.
  • U.S. Pat. No. 6,264,995 described an herbal composition for reducing inflammation in bones and joints by inhibiting the enzyme cyclooxygenase-2.
  • U>S. Patent 8420132B2 described the combination of curcuminoids and boswellic acid for relieving inflammation and antioxidant scavenging in various diseases such as cancer and inflammatory bowel disease.
  • compositions are prepared from tetrahydrocurcumin and other hydrogenated curcumins that are complexed with beta-cyclodextrin, from hemp extracted cannabidiol with beta-caryophyllene that is complexed with beta-cyclodextrin. These complexes can then be incorporated into a liposomal matrix and dried either as powders or as thin oral dispersible strips for buccal or sublingual delivery to the mammalian patient.
  • the compositions can further comprise other anti-inflammatory polyphenols as are known, other CB2 agonists as are known and other TPRV 1 agonists as are known.
  • 6,841,177 disclosed antiproliferative and photosensitization activities of Curcuma longa extract and its use in proliferative diseases Such as psoriasis, as reducers of plasmatic fibrinogen and the Apolipoprotein B/Apollipopro tein A-I quotient, without altering other coagulation parameters.
  • U.S. Pat. No. 6,440,468 disclosed a method for obtaining apolar and polar extracts of Curcuma and applications thereof.
  • a process for obtaining the apolar extract comprises: (a) extracting the rhizomes with an organic solvent; (b) filtration and evaporation to dryness of the extract; (c) dissolution of the oleoresin obtained in hot conditions, precipitation while allowing to cool down and filtration of the solid; (d) drying and recrystallizing the Solid in order to obtain a product having a purity in curcuminoids higher than
  • a process for obtaining the polar extract comprises (i) extraction of the rhizomes with water at 50-70° C. and (ii) filtration 10 15 25 30 35 40 45 50 55 60 65 4 and evaporation of the water.
  • Application of the compositions and preparations as catchers of free radicals and anti-aging agents, as well as reducing agents to reduce the plasma levels of lipid peroxides in human beings are disclosed.
  • 5,494,668 disclosed a method of treating degenerative musculoskeletal diseases Such as rheumatoid arthritis and osteoarthritis in an animal, typically a human, comprises administering to the animal, typically in a convenient dosage form, a therapeutically effective amount of the beneficiated extracts of the plants ashwagandha (Withania somnifera), Sallaiguggul (Boswellia serrata), turmeric (Curcuma longa), and ginger (Zingiber officinale) in a predetermined proportion relative to each other with or
  • the beneficiated plant extracts are made in accordance with a novel process which is also disclosed.
  • US Patent Application 20030152585A1 disclosed an herbal composition comprising a mixture of herbs such as Tinospora cordifolia, Aloe Vera, Curcuma loraga, Withania Somnifera, Achyranthus asperea, Ocinum sanctum and Picorrhiza Kur roa for treatment of hematological malignancies.
  • U.S. Pat. No. 6,979,470 disclosed curcuminoid compositions comprising an effective amount of a curcuminoid species and an effective amount of a diterpene lactone species, a triterpene species or derivatives thereof that have a synergistic effect on specific inhibition of inducible COX-2 activity and have minimal effect on COX-1 activity.
  • US Patent Application 20040247700A1 disclosed curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2 and this composition is useful for treating e.g. inflammation or arthritis, comprising curcuminoid and diterpene lactone or triterpene, and specifically inhibits inducible cyclooxygenase-2 (COX-2) activity.
  • US Patent Application 20040247700A1 disclosed curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2 and this composition is useful for treating e.g. inflammation or arthritis, comprising curcuminoid and diterpene lactone or triterpene, and specifically inhibits inducible cyclooxygenase-2 (COX-2) activity.
  • COX-2 inducible cyclooxygenase-2
  • curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase. It is also disclosed this composition for treating e.g. inflammation or inflammation-based diseases, comprising curcuminoid species and alpha-acid (hops plant products) or beta-acid (lupulones).
  • US Patent Application 20030108628A1 described curcuminoid compositions, which exhibits synergistic inhibition of the expression and/or activity of cyclooxygenase. It also disclosed this composition for treating e.g. inflammation or arthritis, comprising curcuminoid and diterpene Intone or triterpene, and specifically inhibits inducible cyclooxygenase-2 (COX-2) activity.
  • US Patent Application 20050191375A1 described synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines. It also disclosed the composition for reducing inflammation or treating e.g.
  • photosensitizing, antiproliferative and fibrinogen level reducing activity used e.g. for treating psoriasis is also disclosed.
  • the patent W003007975A1 described curcuminoid compositions, which exhibits synergistic inhibition of the expression and/or activity of cyclooxygenase-2. It also disclosed the composition useful for treating e.g. inflammation or arthritis, comprising curcuminoid and diterpene lactone or triterpene, and specifically inhibits inducible cyclooxygenase-2 (COX 2) activity.
  • the patent W006062681A1 described curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2.
  • the formulation comprises, as a first component an effective amount of a curcuminoid species and an effective amount of a second component being from the group consisting of an alpha-acid species (hops plant products) or beta-acid species (lupulones) or derivatives thereof.
  • W005084230A2 described synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines.
  • the composition useful for reducing inflammation or treating e.g. pain, cancer, rheumatoid arthritis, psoriasis, ulcerative colitis, and conjunctivitis comprises fraction isolated or derived from hops and methylxanthine is disclosed.
  • the patent GB2388539A1 disclosed two polyherbal formulations for treating cancer, comprises a mixture of six or four herbs, or a mixture of active ingredients extracted or synthesized from herbs.
  • the first formulation comprises a mixture of Glycine max, Lycopersicon esculentum, Allium sativum, Curcuma longa, Linum usitatissimum, and Convolvulus arvensis.
  • the second formulation comprises a mixture of Tinospora cordifolia, Withania somnifera, Phyllanthus, and Asparagus racemosus.
  • U.S. Pat. No. 5,629,351 described boswellic acid compositions and preparation thereof.
  • the composition comprises a new fraction containing known boswellic acids and new 2-alpha, 3-alpha-dihydroxy- urs-12-en-24-oic acid is useful as a synergistic anti-inflammatory, antiarthritic and antiulcerogenic agent.
  • the patent AU0075253A5 described novel pharmacological activities of Curcuma longa extracts.
  • the use of an aqueous alcoholic extract of Curcuma longa in a composition having e.g. photosensitizing, antiproliferative and fibrinogen level reducing activity, used e.g. for treating psoriasis is also disclosed.
  • none of the prior art mentioned above relates to a composition comprising complexed curcuminoids combined with complexed cannabidiol/ beta-caryophyllene combinations. It is, therefore, an object of the present invention to provide a safe dietary supplement composition, which alleviates or prevents COX-2 mediated disorders, inflammatory diseases like rheumatoid arthritis, through a synergistic effect of COX 2 inhibition and CB2 and TPRV 1 agonism.
  • the present invention provides a novel synergistic dietary supplement
  • compositions for alleviating COX 2 mediated mammalian disorders provides a dietary synergistic mixture of cyclodextrin complexed curcuminoids, specifically hydrogenated curcuminoids, along with at least a complexed mixture of cannabidiol and beta-caryophyllene.
  • these complexes are cyclodextrin complexes and most preferably these cyclodextrin complexed cannabidiol and beta caryophyllene are contained within a desiccated liposomal matrix.
  • These liposomal matrices can be in powdered form or in the form of oral thin dispersible films for buccal or sublingual delivery of actives.
  • the present invention further provides a dietary synergistic mixture of complexed hydrogenated curcuminoids, and complexed cannabidiol and beta-caryophyllene combination and optionally containing one or more of glucosamine, resVeratrol, garlic extract, chondroitin, bromelain, boswellic acid and quercetin, other anti-inflammatory polyphenols and other CB2 agonists.
  • the present invention further provides for these complexes to preferably be in a desiccated liposomal matrix.
  • These compositions may be administered buccally, sublingually, orally, or rectally across the mucosa through powders, gums, troches, lozenges, thin orally fast dissolving strips and other methods as known in the art.
  • compositions of the above invention synergistically both reduce inflammation and pain in a mammalian subject.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention concerne de nouvelles compositions de compléments alimentaires comprenant des curcuminoïdes complexés combinés avec des cannabidiol complexés, la composition présentant une activité anti-inflammatoire synergique et un soulagement de la douleur. L'invention concerne également de nouvelles compositions comprenant des curcuminoïdes complexés qui ont un effet synergique sur l'inhibition spécifique de l'activité anti-inflammatoire par l'activation de voies synergiques qui sont TPRV 1 et CB2 ainsi que COX2. Facultativement, ces compositions peuvent en outre contenir de l'acide boswellique, de la glucosamine, du resvératrol, de l'extrait d'ail, de la chondroïtine, de la bromélaïne, de la quercétine, de l'acide gallique, l'acide caféique, de l'extrait de thé vert, des polyphénols anti-inflammatoires, des agonistes TPRV 1 supplémentaires, des agonistes de glycine 3 et d'autres agonistes CB2.
PCT/US2020/037133 2019-06-26 2020-06-11 Nouvelle formulation pour le traitement de l'inflammation et de la douleur Ceased WO2020263577A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962866761P 2019-06-26 2019-06-26
US62/866,761 2019-06-26

Publications (1)

Publication Number Publication Date
WO2020263577A1 true WO2020263577A1 (fr) 2020-12-30

Family

ID=74059808

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/037133 Ceased WO2020263577A1 (fr) 2019-06-26 2020-06-11 Nouvelle formulation pour le traitement de l'inflammation et de la douleur

Country Status (1)

Country Link
WO (1) WO2020263577A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115282188A (zh) * 2022-08-30 2022-11-04 中科瑞晟芳香产业研究院(湖北)有限公司 一种含有薰衣草精油的复合精油组合物及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005084230A2 (fr) * 2004-02-27 2005-09-15 Metaproteomics, Llc Compositions pharmaceutiques anti-inflammatoires synergiques et procedes associes utilisant des curcuminoides ou des methylxanthines
WO2016144376A1 (fr) * 2015-03-10 2016-09-15 Nanosphere Health Sciences, Llc Compositions et méthodes à base de nanoparticules lipidiques en tant que support de cannabinoïdes sous des formes posologiques dosées avec précision
US20190046598A1 (en) * 2016-02-04 2019-02-14 Czap Research And Development Llc. Controlled-release and stratified cyclodextrin inclusion complex vehicles

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005084230A2 (fr) * 2004-02-27 2005-09-15 Metaproteomics, Llc Compositions pharmaceutiques anti-inflammatoires synergiques et procedes associes utilisant des curcuminoides ou des methylxanthines
WO2016144376A1 (fr) * 2015-03-10 2016-09-15 Nanosphere Health Sciences, Llc Compositions et méthodes à base de nanoparticules lipidiques en tant que support de cannabinoïdes sous des formes posologiques dosées avec précision
US20190046598A1 (en) * 2016-02-04 2019-02-14 Czap Research And Development Llc. Controlled-release and stratified cyclodextrin inclusion complex vehicles

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SREERAJ ET AL., A UNIQUE FORMULATION OF HYDROGENATED CURCUMINOIDS WITH HIGHER BIOAVAILABILITY AND THE APPLICATION IN FOOD MATRICES, vol. 6, no. 2, 17 March 2016 (2016-03-17), pages 1 - 4, XP055778737, DOI: 10.4172/2155-9600.1000478 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115282188A (zh) * 2022-08-30 2022-11-04 中科瑞晟芳香产业研究院(湖北)有限公司 一种含有薰衣草精油的复合精油组合物及其制备方法

Similar Documents

Publication Publication Date Title
US8192768B2 (en) Synergistic anti-inflammatory and antioxidant dietary supplement compositions
US11903991B2 (en) Synergistic dietary supplement compositions for the prevention, treatment or control of inflammatory disorders
Anilkumar 10. Ethnomedicinal plants as anti-inflammatory and analgesic agents
Khayyal et al. Micellar solubilisation enhances the antiinflammatory activities of curcumin and boswellic acids in rats with adjuvant-induced arthritis
EP2175871B1 (fr) Composition synergique d'origine végétale pour le traitement de troubles rhumatismaux et musculo-squelettiques (rmsds)
Dugani et al. Effects of the oil and mucilage from flaxseed (linum usitatissimum) on gastric lesions induced by ethanol in rats
Mahmood et al. Phytochemical and Antioxid ant Screening of Anacylus Pyrethrum, Apium Graveolens, Boerhaavia Diffusa, Cinnamomum Cassia Blume, Cuscumis Melo Linn, Cuscum is Sativus Linn, Daucus Sativus, Foeniculum Vulgare, Trachyspermum Ammii and Theit effect on various Human Ailments
Kamel et al. Phytochemical screening, acute toxicity, analgesic and anti-inflammatory effects of apricot seeds ethanolic extracts
Geszke-Moritz et al. Role of plant materials with anti-inflammatory effects in phytotherapy of osteoarthritis
WO2020263577A1 (fr) Nouvelle formulation pour le traitement de l'inflammation et de la douleur
Raju et al. Therapeutic and Pharmacological Efficacy of Achyranthes aspera Linn.: An Updated Review.
Kumar et al. Bioactive effects and safety profiles of fenugreek (Trigonella foenum-graecum L.) for pharmaceutical and medicinal applications
Upadhyay Anti-arthritic potential of plant natural products; its use in joint pain medications and anti-inflammatory drug formulations
Maksimović On Frankincense
Kumari et al. Boswellia serrata ROXB. EX COLEBR.(Salai): an Ayurvedic herb with anti-inflammatory potential
Bello et al. Anti-ulcer activity of ethanol root extracts of Cassia sieberiana DC In albino rats
Thanigavelan et al. An overview of the Herbs in a Siddha Polyherbal decoction-Pidangunaari Kudineer indicated for Hepatomegaly
Ratnam et al. Traditional uses and pharmacology of Boswellia species
Lim Alpinia officinarum
Gautam et al. Pre-clinical/animal studies conducted on Turmeric and Curcumin and their formulations
Ahmad et al. Reviews of herbal and their secondary metabolites in the treatment of ulcerative colitis and peptic ulcer
Rani et al. Anti‐Inflammatory, Antimicrobial Activities and Phytochemical Analysis of the Tuber Extracts of Dioscorea oppositifolia Linn
Nigam et al. Ginger (6-gingerol)
Mahajan et al. Ethnobotanical and pharmacological study of Gymnema sylvestre
Oomah Analgesic Plants

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20831728

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20831728

Country of ref document: EP

Kind code of ref document: A1